Porownywarka
Enfuvirtide vs LL-37 side-by-side
Zestaw do czterech peptydów według statusu dowodów, mechanizmów, dawkowania z badań, skutków ubocznych i referencji.
Porownywarka
Zestaw do czterech peptydów według statusu dowodów, mechanizmów, dawkowania z badań, skutków ubocznych i referencji.
Wybrane (2/4)
Udostępnij porównanie peptydów
| Wlasciwosc | Enfuvirtide | LL-37 |
|---|---|---|
| Kategoria | Odporność | Odporność |
| Znany tez jako | Fuzeon, T-20 | Cathelicidin, CAP18 |
| Zatwierdzony przez FDA | Tak | Nie |
| Status kliniczny | FDA approved; source also reports commercial discontinuation in February 2025 and withdrawal from US, UK, and Canadian markets.
| Investigational; source notes clinical trials for wound healing and FDA Category 2 restricted status due to limited safety data and immunogenicity concerns.
|
| Czego oczekiwac | HIV treatment, viral infection management | Antimicrobial, infections, biofilm disruption, wound healing |
| Jak dziala | Enfuvirtide is described as a peptide HIV fusion inhibitor that targets gp41. It resembles the HR2 segment of gp41 and binds the HR1 region, disrupting the conformational pairing needed to draw viral and host-cell membranes together. Because that fusion step is blocked, the virus is prevented from entering the cell through this pathway. | LL-37 is described as a positively charged, amphipathic host-defense peptide that can associate with negatively charged microbial membranes and disrupt them. Beyond direct antimicrobial effects, the source reports signaling roles that include neutralizing bacterial LPS, shaping inflammatory activity, recruiting immune cells to sites of injury or infection, and supporting epithelial repair. The source notes production in epithelial tissues such as skin, gut, and lung, as well as immune cells including neutrophils. |
| Typowe dawkowanie | Limited community data available · See research protocols | 100-200 mcg daily · Once daily |
| Dawkowanie z badań | 90 mg subcutaneous twice daily · Twice daily · Ongoing as part of HIV regimen · Subcutaneous injection twice daily | 100-200 mcg subcutaneous · Variable by protocol · Subcutaneous injection or topical |
| Typowy czas trwania | Ongoing as part of HIV regimen | Variable by protocol |
| Podanie | Subcutaneous injection twice daily | Subcutaneous injection or topical |
| Timing | Morning or as directed With or without food | Morning With or without food |
| Poziom dowodów | Zatwierdzone przez FDA | Badania kliniczne |
| Mozliwe skutki uboczne |
+3 więcej
|
+4 więcej
|
| Podsumowanie researchu | The source characterizes enfuvirtide as a well-studied antiretroviral peptide rather than a speculative research compound. It cites the TORO 1 and TORO 2 phase 3 trials in heavily treatment-experienced participants, where enfuvirtide added to an optimized background regimen produced larger viral-load reductions than optimized background therapy alone. The source also notes earlier dose-ranging studies in HIV-infected adults, frequent injection-site reactions, practical burden from twice-daily injections, resistance linked to gp41 HR1 mutations, and combination-regimen use. | The source presents LL-37 as a well-studied endogenous component of human innate immunity, with literature support for broad antimicrobial activity, membrane disruption, and distribution across epithelial and immune tissues. It also reports exploratory research on LL-37 or related mimics in laboratory anticancer models, Helicobacter pylori host-defense research, and ocular-surface pathogen contexts. The evidence described is strongest for LL-37 as a natural immune peptide; deliberate administration remains experimental in the supplied source, and the source flags that LL-37 may worsen inflammation in some disease settings. |
| Referencje | ||
| Pełny profil | Zobacz szczegóły | Zobacz szczegóły |
Zapisz to porównanie
Trzymaj ten zestaw researchowy pod reka na darmowym koncie PeptiGuide.
Zapisz porównanie - darmowe kontoTrackuj swoja ścieżkę peptydówa
Zamien research w prywatny log protokołu, gdy będziesz gotowy.
Trackuj ścieżkę peptydówaWyłącznie edukacyjnie. Te informacje są agregowane z publicznych badań i raportów społeczności. To nie jest poradą medyczną, a informacje o dawkowaniu są opisowe, nie rekomendacyjne. Zawsze konsultuj się z wykwalifikowanym specjalistą ochrony zdrowia.